INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Anavex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 14, 2025, Anavex issued a press release announcing that "[t]he Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation." 

On this news, Anavex's stock price fell $2.05 per share, or 35.94%, to close at $3.65 per share on November 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-anavex-life-sciences-corp---avxl-302619327.html

SOURCE Pomerantz LLP